MX2023008029A - Proteinas de fusion de anticuerpo y sialidasa-pd-1 y metodos para utilizarlas. - Google Patents
Proteinas de fusion de anticuerpo y sialidasa-pd-1 y metodos para utilizarlas.Info
- Publication number
- MX2023008029A MX2023008029A MX2023008029A MX2023008029A MX2023008029A MX 2023008029 A MX2023008029 A MX 2023008029A MX 2023008029 A MX2023008029 A MX 2023008029A MX 2023008029 A MX2023008029 A MX 2023008029A MX 2023008029 A MX2023008029 A MX 2023008029A
- Authority
- MX
- Mexico
- Prior art keywords
- sialidase
- fusion proteins
- antibody
- methods
- antibody conjugates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Environmental Sciences (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163134415P | 2021-01-06 | 2021-01-06 | |
| PCT/US2022/011487 WO2022150507A1 (en) | 2021-01-06 | 2022-01-06 | Sialidase-pd-1-antibody fusion proteins and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023008029A true MX2023008029A (es) | 2023-08-25 |
Family
ID=82357533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023008029A MX2023008029A (es) | 2021-01-06 | 2022-01-06 | Proteinas de fusion de anticuerpo y sialidasa-pd-1 y metodos para utilizarlas. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240059773A1 (enExample) |
| EP (1) | EP4274891A4 (enExample) |
| JP (1) | JP2024501770A (enExample) |
| KR (1) | KR20230142722A (enExample) |
| CN (1) | CN116867896A (enExample) |
| AU (1) | AU2022205638A1 (enExample) |
| CA (1) | CA3172941A1 (enExample) |
| IL (1) | IL304228A (enExample) |
| MX (1) | MX2023008029A (enExample) |
| WO (1) | WO2022150507A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7462560B2 (ja) | 2018-01-03 | 2024-04-05 | パレオン ファーマシューティカルズ インコーポレイテッド | 組換えヒトシアリダーゼ、シアリダーゼ融合タンパク質およびそれらの使用方法 |
| EP4744681A1 (en) | 2024-08-16 | 2026-05-20 | Shanghai Bao Pharmaceuticals Co., Ltd. | COMPLEX TARGETING TARGET CELLS AND ITS USE |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180271997A1 (en) * | 2016-05-31 | 2018-09-27 | Tianxin Wang | Methods and Reagents to Treat Tumor and Cancer |
| CN111263769B (zh) * | 2017-07-10 | 2024-01-02 | 先天制药公司 | Siglec-9中和性抗体 |
| JP7462560B2 (ja) * | 2018-01-03 | 2024-04-05 | パレオン ファーマシューティカルズ インコーポレイテッド | 組換えヒトシアリダーゼ、シアリダーゼ融合タンパク質およびそれらの使用方法 |
| US20250049846A1 (en) * | 2019-01-03 | 2025-02-13 | Palleon Pharmaceuticals Inc. | Methods and compositions for treating cancer with immune cells |
| CN114245807B (zh) * | 2019-06-25 | 2025-05-02 | 吉利德科学公司 | Flt3l-fc融合蛋白和使用方法 |
-
2022
- 2022-01-06 CN CN202280016348.2A patent/CN116867896A/zh active Pending
- 2022-01-06 WO PCT/US2022/011487 patent/WO2022150507A1/en not_active Ceased
- 2022-01-06 EP EP22737122.6A patent/EP4274891A4/en not_active Withdrawn
- 2022-01-06 CA CA3172941A patent/CA3172941A1/en active Pending
- 2022-01-06 US US18/260,378 patent/US20240059773A1/en active Pending
- 2022-01-06 JP JP2023540926A patent/JP2024501770A/ja active Pending
- 2022-01-06 MX MX2023008029A patent/MX2023008029A/es unknown
- 2022-01-06 AU AU2022205638A patent/AU2022205638A1/en not_active Abandoned
- 2022-01-06 KR KR1020237026708A patent/KR20230142722A/ko not_active Withdrawn
-
2023
- 2023-07-04 IL IL304228A patent/IL304228A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022205638A1 (en) | 2023-07-20 |
| JP2024501770A (ja) | 2024-01-15 |
| EP4274891A1 (en) | 2023-11-15 |
| US20240059773A1 (en) | 2024-02-22 |
| IL304228A (en) | 2023-09-01 |
| CN116867896A (zh) | 2023-10-10 |
| EP4274891A4 (en) | 2025-01-08 |
| WO2022150507A1 (en) | 2022-07-14 |
| KR20230142722A (ko) | 2023-10-11 |
| CA3172941A1 (en) | 2022-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021015880A (es) | Fragmentos de unión al antígeno cd3 y composiciones que comprenden los mismos. | |
| EA202092825A1 (ru) | Анти-sirpa антитела и способы их применения | |
| CO2020014773A2 (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
| CL2023001064A1 (es) | Proteína de unión al antígeno anti-steap1 | |
| BR112022009273A2 (pt) | Imunoglobulinas modificadas para direcionar depósitos amiloides | |
| PE20211491A1 (es) | PROTEINAS DE FIJACION A SIRPa Y METODOS DE USO DE ESTAS | |
| MX2020002921A (es) | Anticuerpos para claudin6 y métodos para tratar el cáncer. | |
| CL2024002250A1 (es) | Uso de anticuerpo anti-vd1 para tratar cáncer, una enfermedad infecciosa o una enfermedad inflamatoria. | |
| EA202190138A1 (ru) | Анти-sirp-бета1 антитела и способы их использования | |
| BR112021008060A2 (pt) | Polipeptídeo, anticorpo anti-ctla4 ou fragmento de anticorpo, imunoconjugado, composição farmacêutica, dose única de composição farmacêutica, método de tratar câncer, e, kit para diagnóstico ou tratamento | |
| CR20230169A (es) | ANTICUERPOS ANTI-TREM2 Y MÉTODOS PARA UTILIZARLOS (divisional 2019-0485) | |
| MX2021011330A (es) | Anticuerpos de claudina-6 y conjugados de fármacos. | |
| EA202091054A1 (ru) | Слитые молекулы на основе антитела против pd-l1 и ил-7 | |
| MX2023008027A (es) | Proteinas de fusion de sialidasa y anticuerpo her2 y metodos de uso de estas. | |
| PE20131376A1 (es) | Anticuerpos para metaloproteinasa-9 de matriz | |
| CO2020013833A2 (es) | Anticuerpo anti-muerte programada-ligando 1 y su uso | |
| EA202190235A1 (ru) | Антитела к cd33 и способы их применения | |
| AR115257A1 (es) | Anticuerpos de fijación a bcma y sus usos | |
| CO2018012652A2 (es) | Anticuerpos anti-fcrn madurados de afinidad humanizada | |
| MX2022002672A (es) | Anticuerpo anti-vsig4 o fragmento de union a antigeno y usos del mismo. | |
| CR20210324A (es) | Anticuerpos anti-pmel 17 y conjugados de los mismos | |
| MX2021004045A (es) | Metodos para tratar cancer con una combinacion de un anticuerpo anti factor de crecimiento endotelial vascular (vegf) y un conjugado de anticuerpo anti factor tisular-farmaco. | |
| CO2022008314A2 (es) | Anticuerpos anti–mertk y métodos de uso de los mismos | |
| PE20200927A1 (es) | Anticuerpos monoclonales que se unen a la region de la cadena beta de la familia trbv9 del receptor de las celulas t humanas | |
| PE20230602A1 (es) | Anticuerpos anti-sea de muc1 |